Zealand Pharma A/S (OTCMKTS:ZLDPF) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) in a research report sent to investors on Tuesday, Marketbeat Ratings reports. The brokerage issued an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Zealand Pharma A/S’s FY2024 earnings at ($2.53) EPS.

Separately, BTIG Research initiated coverage on shares of Zealand Pharma A/S in a research note on Thursday, March 7th. They set a buy rating on the stock.

Zealand Pharma A/S Price Performance

Shares of ZLDPF stock opened at $84.25 on Tuesday. The firm’s 50-day moving average is $91.80 and its two-hundred day moving average is $73.59. Zealand Pharma A/S has a 12 month low of $33.42 and a 12 month high of $111.44. The company has a market capitalization of $4.34 billion, a PE ratio of -46.29 and a beta of 0.67.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.08). The company had revenue of $3.35 million during the quarter, compared to analysts’ expectations of $1.97 million. Zealand Pharma A/S had a negative net margin of 213.77% and a negative return on equity of 41.49%. Sell-side analysts forecast that Zealand Pharma A/S will post -2.54 EPS for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.